Extrait

ITSELF: Phase Ib study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (Selicrelumab) in combination with anti-PD-L1 (Atezolizumab) in patients with refractory or relapsed B cell lymphoma

Liens

• e-cancer.fr
• Fiche de l'U.S. National Library of Medicine (NLM), sur ClinicalTrials.gov